TCRX Q4 2022 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+8.4% YoY

Gross Profit

$2M52.1% margin

Operating Income

-$19M-602.6% margin

Net Income

-$19M-604.9% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

-8.0%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$199M

Total Liabilities

$100M

Stockholders' Equity

$99M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	+8.4%
Gross Profit	$2M	-$10M	+116.5%
Operating Income	-$19M	-$14M	-31.3%
Net Income	-$19M	-$14M	-31.9%